SKP2 (S-phase kinase-associated protein 2) inhibitor; upregulates p27 and arrests cell cycle in G1 phase
SMIP 004 is a SKP2 (S-phase kinase-associated protein 2) inhibitor. Upregulates p27 and activates the unfolded protein response (UPR) in LNCaP prostate cancer cells overexpressing SKP2. Also induces oxidative stress. Induces proteasomal degradation of cyclin D1 and acts as CDK2 inhibitor. Arrests cell cycle in G1 phase and induces apoptosis in prostate cancer cells, but not normal cells
in vitro
. Inhibits growth of breast and prostate cancer xenografts in mice. Also induces autophagy and reduces replication of MERS-CoV in VeroB4 cells.
| Marque | Tocris |
|---|---|
| Réf. B-LABO | BL-RE-124603 |
| Réf. fabricant | 18787506 |
| Nom chimique ou matériau | N-(4-Butyl-2-methylphenyl)acetamide |
| CAS | 143360-00-3 |
| Quantité | 50 mg |
| Cible | Ubiquitin Ligase (E3) Inhibitors |
| Formule moléculaire | C<sub>13</sub>H<sub>19</sub>NO |
| Pureté | 0.98 |
